You are here
Help eliminate barriers to cost with the Janssen CarePath Savings Program for INVOKAMET® XR and INVOKAMET® (canagliflozin/metformin HCl)
Preferred coverage* for most commercial and Medicare Part D patients†
- Per calendar year, subject to a $3,000 maximum annual benefit
- Continuing support may also be available for eligible patients
For eligibility requirements and restrictions, visit Janssen CarePath Savings Program for INVOKAMET® XR and INVOKAMET® or call
‡The Savings Card is not available to patients enrolled in federally subsidized healthcare programs that cover prescription drugs, including Medicare, Medicaid, TRICARE, or other federal or state programs.
Help your patients with a free 30-day trial offer
*Coverage that makes brand-name medications available at a lower co-payment than Tier 3 brand-name drugs. Tier 1 medications are usually generics with low co-payments.
†Data on file. Janssen Pharmaceuticals, Inc. MMIT as of April 8, 2016. Commercial and Medicare detail exports.
If your patients are currently uninsured
Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is committed to providing access to uninsured individuals who lack the financial resources to pay for their medicines. If your patient needs INVOKAMET® XR or INVOKAMET® and is uninsured and unable to pay for their medicine, please have them contact a JJPAF program specialist at
If your patients have questions about affording their medication, a comprehensive list of additional programs is available at JanssenPrescriptionAssistance.com/INVOKANA.
Learn about COVERAGE AND ACCESS